Cancer Treatment · global
First Human Observations of Intratumoral N17350: Five Uninjected Lesions No Longer Detectable on Imaging in One Patient
Onchilles reported no dose-limiting toxicities in the first three participants, with a response in distant lesions also observed in one patient with Merkel cell carcinoma. This offers clues about whether local treatment can trigger a systemic anticancer response, but efficacy and the immune mechanism remain to be established.
Can injecting a drug into one tumor help the immune system recognize cancer cells elsewhere? On November 6, Onchilles Pharma announced the first human observations of its experimental therapy N17350: after intratumoral injection, five uninjected lesions in a patient with Merkel cell carcinoma were no longer detectable on imaging at week eight. This response beyond the site of local treatment warrants further validation, but it cannot yet establish systemic efficacy.
The data come from the Phase I/II OP-NEU-101 trial and are scheduled for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting. According to the company’s announcement, the first three patients, who had received multiple prior lines of treatment, received N17350 at a concentration of 1 milligram per milliliter. All completed the dose-limiting toxicity assessment period without such toxicities. This supports continued exploration of higher doses, but does not mean there were no side effects and is insufficient to establish long-term safety.
The evidence suggesting efficacy centers on that single case. The patient’s disease had continued to progress after treatment that included avelumab and radiation therapy; of the six lesions evaluated in this study, only one was injected. Investigators assessed the lesions using RECIST 1.1 criteria, and the other five were all no longer detectable at week eight. One was a precisely measured lesion, while the other four were monitored for their presence or absence. This result cannot be directly equated with the patient achieving a systemic complete response or the cancer having been eradicated.
N17350 is an engineered elastase derived from an enzyme found in human neutrophils. According to the company’s design, it first destroys cancer cells, then allows antigens released by the tumor to serve as material for immune recognition, in an attempt to initiate a response within the body against the patient’s tumor. Turning a tumor into an “in situ vaccine” remains a therapeutic concept that requires confirmation in human studies.
Preliminary testing detected no active N17350 in the plasma samples collected and found no newly emerging antidrug antibodies after treatment. These findings can inform investigations of drug distribution and immune responses, but the absence of detectable drug in the blood alone cannot prove that the changes in uninjected lesions were necessarily caused by the immune system.
Trial information from the US National Cancer Institute confirms that OP-NEU-101 (NCT07339176) uses an open-label design, first identifying a suitable dose and then expanding enrollment to assess safety and preliminary antitumor activity. Participants receive intratumoral injections every two weeks for eight or twelve weeks, with responses monitored through imaging, blood sampling and, when necessary, tumor sampling.
The patient results currently available come from the company’s announcement; BioSpace published the same press release, which does not constitute independent verification, while the National Cancer Institute page provides only the trial design. The next questions are whether responses in uninjected lesions can be reproduced in more patients, how long they can last, and what risks emerge at higher doses. This evidence will determine whether the concept of a local injection triggering a broader anticancer response can gradually become a reliable treatment strategy.